This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

Meningitis

  1. PATH is on the front lines of an effort to defeat meningitis by 2030.
    Published: November 2021
    Type: Article
  2. Together with over 400 external stakeholders from across 50 countries, PATH has crafted a new institutional strategy that responds to the current crises we face as a global community, to the needs and priorities of our local partners, and to the resounding calls for the continued transformation of our sector. To bring our new strategy to life for our external partners, we’ve developed a strategy brochure. The brochure explains why PATH exists (our mission), what we will do (our priorities) and, perhaps most importantly, how we will do it (our change strategies).
    Published: June 2021
    Type: Resource Page
  3. Results from a Phase 2 clinical study of a pentavalent meningococcal meningitis vaccine designed for use in the African meningitis belt demonstrate the vaccine candidate to be safe, well-tolerated, and capable of producing strong immune responses to all five serogroups.
    Published: June 2021
    Type: Announcement
  4. Over the last decade, product development partnerships (PDPs) have produced a wide assortment of lifesaving technologies targeting diseases that afflict billions in low-income countries. This report from a group of 12 PDPs, including PATH, finds that since 2010 these 12 PDPs have developed and brought to market 66 new drugs, vaccines, diagnostics and other technologies for a number of diseases—including tuberculosis, malaria, HIV, meningitis and sleeping sickness—that have reached and benefitted more than 2.4 billion people in low-income countries.The report identifies key factors in the success these organizations, such as developing products that are affordable and easy to administer and leveraging vast networks of partners to cost-effectively develop products. It also documents the contribution of PDPs to building a global ecosystem for health research, noting the 12 organizations helped build research capacity at 550 sites in 80 countries. With increased funding and political support, PDPs can ensure the promise of their current pipelines are realized and that the next wave of critical new technologies complete development and reach those in need.PATH provided a case study on the development of MenAfriVac®, the first vaccine to be developed for meningitis specifically for Africa, which virtually eliminated meningitis across the majority of the African meningitis belt.
    Published: January 2021
    Type: Resource Page
  5. The international community has committed to defeat meningitis by 2030. But how do we get there, and what will it take?
    Published: January 2021
    Type: Article
  6. The COVID-19 pandemic was undoubtedly the public health story of the year—but it wasn’t the only one.
    Published: December 2020
    Type: Article
  7. Serum Institute of India’s pneumococcal conjugate vaccine, PNEUMOSIL®, has received marketing authorization in India—adding a quality-certified and more affordable option to the country’s pneumonia prevention toolkit.
    Published: August 2020
    Type: Announcement
  8. Can a vaccine for pregnant moms protect their babies from dangerous bacterial infections? PATH’s Mark Alderson believes it can.
    Published: May 2020
    Type: Article
  9. COVID-19 is disrupting immunization programs in the communities that count on them most. Despite the pandemic, PATH is working to protect and continue this lifesaving service.
    Published: April 2020
    Type: Article
  10. PATH is part of a global task force working to eliminate meningitis as a public health threat by 2030
    Published: February 2020
    Type: Article
Load more